Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Bombesin Analog Tracers
Overview
Bombesin analog tracers are synthetic peptides based on the 14-amino acid amphibian peptide bombesin or its mammalian counterpart gastrin-releasing peptide (GRP), radiolabeled for molecular imaging. These analogs bind to GRP receptors, which are overexpressed in prostate, breast, and small cell lung cancers, enabling tumor visualization via PET or SPECT imaging.
Mechanism of Action
Various radionuclides including gallium-68, fluorine-18, technetium-99m, and copper-64 have been conjugated to bombesin antagonist and agonist peptides.
Research Summary & Key Findings
Phase 1 and Phase 2 clinical trials have evaluated multiple bombesin analogs including 68Ga-RM2, 68Ga-SB3, and 99mTc-DB4 for imaging prostate cancer and breast cancer, with results published in the Journal of Nuclear Medicine and European Journal of Nuclear Medicine between 2007 and 2020. While these agents demonstrate receptor-specific tumor uptake and acceptable safety, none have achieved regulatory approval, largely due to competition from PSMA-targeted tracers in prostate cancer imaging.
Clinical Status
Bombesin Analog Tracers is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Bombesin Analog Tracers"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Bombesin Analog Tracers"
Registered interventional and observational studies, including status and phase.
- PubChem: "Bombesin Analog Tracers"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Diagnostic
Pentagastrin
FDA ApprovedA synthetic pentapeptide containing the C-terminal tetrapeptide sequence of gastrin (Trp-Met-Asp-Phe-NH2) linked to beta...
View detailsGadopentetate Peptide Conjugates
Research PhaseGadopentetate peptide conjugates consist of the gadolinium-based contrast agent gadopentetate dimeglumine chemically lin...
View detailsDOTATATE (Ga-68)
FDA ApprovedGallium-68 DOTATATE is a radiolabeled somatostatin analog consisting of an octapeptide (Tyr3-octreotate) conjugated to t...
View detailsRGD Peptide Tracers
In Clinical TrialsRGD peptide tracers are short synthetic peptides containing the arginine-glycine-aspartic acid (RGD) tripeptide sequence...
View detailsNo lawful pathway today
Bombesin Analog Tracers is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.